Is RA Treatment Addressing the Real Needs of Patients?

Introduction/Overview

Improvements in Disease Activity Score Associated With Quality of Life Improvements

Daily-Life Burdens With Arthritis

Unmet Needs: Flares

Unmet Needs: The Burden of Disease (Fatigue)

RA Treatment Goals in the 21th Century

Rieke Alten's "Rheuma School"

Findings From a Literature Review on RA and Physical Activity

RA Patient-Centric Approach to Care

Identifying the High-Risk Patient: Progression Associated With ACPA Positivity

Evolution of Ever More Effective RA Therapies

In Some Patients Dose Reduction May Result in Resumption of Disease Activity

The Concept of Immunological Tolerance in The Context of RA

Fast-Tracking Patients With High-Risk Early Rheumatoid Arthritis

Choosing The Right Pro-Inflammatory Target: Often a Matter of Empirical Testing

JAK Inhibitors in RA

JAK Inhibitors: Safety Considerations

Comparing Clinical Results of JAK 1 / 3 and JAK 1 / 2 Inhibitors

Biomarker Matrices: SWEFOT Results

The Future of Biomarkers in RA

Potential Role of Synovial Biopsy in RA Drug Development And Clinical Practice

Patient-Reported Outcomes Assessed in RA Clinical Trials (2012-2014)

RA-BEAM: PRO Improvement With Baricitinib

The RAPID3 Patient-Reported Outcomes Index

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)